OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
55 hedge funds and large institutions have $154M invested in OncoMed Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 15 closing their positions.
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
132% more capital invested
Capital invested by funds: $66.3M → $154M (+$87.4M)
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
4% more funds holding
Funds holding: 53 → 55 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$12.8M |
| 2 |
CCI
Columbus Circle Investors
|
+$6.33M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.83M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$2.94M |
| 5 |
Primecap Management
Pasadena,
California
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$4.14M |
| 2 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
-$1.53M |
| 3 |
JP Morgan Chase
New York
|
-$1.53M |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.49M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.38M |
OMED Hedge Fund Activity: Q4 2013 in Review
55 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2013, worth a combined $154M — up 132% from $66.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OMED positions and 15 closed out — a net gain of 2 holders — while 25 added to existing stakes and 8 trimmed.
The largest buyer was BVF Inc, adding an estimated $12.8M. The largest seller was CR Intrinsic Investors, exiting entirely with an estimated $4.14M sold.
- 55 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2013, up from 53 in Q3 2013.
- Funds reported $154M of OncoMed Pharmaceuticals, Inc. stock for Q4 2013, up 132% quarter-over-quarter.
- 17 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2013 and 15 closed out, a net change of +2 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2013 was BVF Inc, an estimated $12.8M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2013 was CR Intrinsic Investors, an estimated $4.14M sold.
Based on aggregated 13F filings for Q4 2013.